The PROGRESS trial three years later: time for a balanced report of effectiveness.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke--Blood Pressure) randomised controlled trial.BMJ (Clinical research ed.) · 2016
   Trial
2. Controversies: Stroke Prevention in Chronic Kidney Disease.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2021
   Review
3. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis.International archives of medicine · 2009
   Article
4. Delapril plus indapamide: a review of the combination in the treatment of hypertension.Clinical drug investigation · 2007
   Review
5. Applicability to primary care of national clinical guidelines on blood pressure lowering for people with stroke: cross sectional study.BMJ (Clinical research ed.) · 2006
   Article
6. Perindopril monotherapy and PROGRESS in Europe.BMJ (Clinical research ed.) · 2005
   Article
7. Trial protocols: time for more than tinkering.BMJ (Clinical research ed.) · 2005
   Article
8. Users' guide to detecting misleading claims in research: misleading claims may be symptom of even more serious flaws.BMJ (Clinical research ed.) · 2005
   Article
9. Progress in the identification of stroke-related genes: emerging new possibilities to develop concepts in stroke therapy.CNS drugs · 2005
   Review
10. The PROGRESS trial three years later: all aspects of secondary prevention after stroke need to be improved.BMJ (Clinical research ed.) · 2004
    Article
11. The PROGRESS trial three years later: HOPE trial may shed some light.BMJ (Clinical research ed.) · 2004
    Article
12. The PROGRESS trial three years later: Clear and accurate interpretations of studies are needed.BMJ (Clinical research ed.) · 2004
    Article
13. The PROGRESS trial three years later: evangelism is understandable.BMJ (Clinical research ed.) · 2004
    Article
14. The PROGRESS trial three years later: time for more action, less distraction.BMJ (Clinical research ed.) · 2004
    Article

Corrections and comments

• Commented on by
  The PROGRESS trial three years later: time for more action, less distraction.2004
• Commented on by
  The PROGRESS trial three years later: HOPE trial may shed some light.2004
• Commented on by
  The PROGRESS trial three years later: all aspects of secondary prevention after stroke need to be improved.2004
• Commented on by
  The PROGRESS trial three years later: evangelism is understandable.2004
• Commented on by
  The PROGRESS trial three years later: Clear and accurate interpretations of studies are needed.2004
• Commented on by
  Perindopril monotherapy and PROGRESS in Europe.2005

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as